Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years-Reference-Cited by-同舟云学术

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

Published:2010-03-04 Issue:7 Volume:248 Page:943-956
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Spielberg Leigh,Leys Anita

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

http://link.springer.com/content/pdf/10.1007/s00417-009-1256-6.pdf

Reference41 articles.

1. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598–614. doi: 10.1001/archopht.122.4.598 122/4/598 [pii]

2. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857. doi: S0002-9394(07)00718-0 [pii] 10.1016/j.ajo.2007.08.012

3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65 e55. doi: S0161-6420(08)01075-0 [pii] 10.1016/j.ophtha.2008.10.018

4. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532–1542. doi: 124/11/1532 [pii] 10.1001/archopht.124.11.1532

5. Schmidt-Erfurth U, Wolf S (2008) Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92:1628–1635. doi: bjo.2007.135277 [pii] 10.1136/bjo.2007.135277

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age-Related Macular Degeneration and its Current Treatment Strategies: An Updated Review;Macular Diseases - An Update;2024-02-09

2. Review of Fibrosis in Neovascular Age-Related Macular Degeneration;American Journal of Ophthalmology;2023-02

3. Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD;British Journal of Ophthalmology;2020-12-21

4. Efficacy of ranibizumab combined with photodynamic therapy on wet age‑related macular degeneration;Experimental and Therapeutic Medicine;2020-04-02

5. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment;Clinical Ophthalmology;2018-09